

**GOVERNMENT OF INDIA  
MINISTRY OF HEALTH AND FAMILY WELFARE  
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**LOK SABHA  
STARRED QUESTION NO.94  
TO BE ANSWERED ON THE 3<sup>RD</sup> DECEMBER, 2021  
MUCORMYCOSIS AND DENGUE CASES**

†\*94. SHRIMATI KESHARI DEVI PATEL:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

- (a) the number of cases of Black Fungus or Mucormycosis reported till date in each State/UT including Prayagraj in Uttar Pradesh and Jamui in Bihar;
- (b) the steps taken by the Government to tackle such cases;
- (c) the preventive measures initiated by the Government in controlling and treating the increasing number of dengue cases in the country;
- (d) whether the Government has any proposal to provide special package to States/UTs in order to enhance the treatment facilities being provided to Dengue patients; and
- (e) if so, the details thereof, State/UT-wise particularly in Rajasthan, Uttar Pradesh and Bihar?

**ANSWER  
THE MINISTER OF HEALTH AND FAMILY WELFARE  
(DR. MANSUKH MANDAVIYA)**

(a) to (e) A Statement is laid on the Table of the House.

**STATEMENT REFERRED TO IN REPLY TO LOK SABHA  
STARRED QUESTION NO. 94\* FOR 3<sup>RD</sup> DECEMBER, 2021**

(a) to (e) A total of 51,775 cases of Mucormycosis have been reported till 29<sup>th</sup> November 2021. State wise cases of Mucormycosis reported till 29<sup>th</sup> November 2021 are at Annexure 1.

Further, 28 cases have been reported in Prayagraj, UP & 2 cases of Mucormycosis are reported in Jamui, Bihar.

Health is a state subject. Union Ministry of Health has proactively supported states to tackle the challenge posed by cases of Mucormycosis during the second surge of Covid-19.

MOHFW had asked all states vide DO letter dated 19<sup>th</sup> May and 24<sup>th</sup> May to make Mucormycosis a notifiable disease so as get details of Mucormycosis incidence in the country. A unified portal was created by MoHFW for States to enter surveillance data of Mucormycosis cases.

The Ministry of Health & Family Welfare has issued national comprehensive guidelines for the management of post covid sequelae including mucormycosis as available on

<https://www.mohfw.gov.in/pdf/NationalComprehensiveGuidelinesforManagementofPostCovidSequelae.pdf>.

The clinical management guidelines for managing COVID-19 cases by Ministry of Health & Family Welfare advocates rational use of steroids for managing moderate to severe cases of COVID-19 under strict medical supervision. Further noting relationship between use of steroids and other immune-suppressive drugs “Advisory for rational use of Steroids and Tocilizumab in the treatment of Covid -19 patients” was issued by Directorate General of Health Services.

Since early May, 2021 the details of production, stock, supplies made and purchase orders were obtained from the manufacturers and their co-operation was sought to overcome the gap between supply and demand.

Department of Pharmaceuticals (DoP), Central Drugs Standard Control Organisation (CDSCO) & National Pharmaceutical Pricing Authority (NPPA) have been jointly monitoring the production and availability of critical (COVID) drugs including Amphotericin-B injections.

Central Government has placed Amphotericin B under restricted category for export vide Notification dated 1st June, 2021 for ensuring continuous availability of medicines for treatment of Mucormycosis cases domestically.

Central Government has undertaken steps to procure the Amphotericin-B from various available sources around the globe and made efforts to increase the production of existing Manufacturers/Importers for the said drug in the country.

Central Drugs Standard Control Organisation (CDSCO) under MoHFW has given permission to 11 new manufacturers of Liposomal Amphotericin- B. A total of 16,08,291 vials of Liposomal Amphotericin-B were jointly allocated by Dept. of Pharmaceuticals and MoHFW to various States/UTs up to 24th July 2021 on commercial basis.

Further, 3 lakhs vials of Liposomal Amphotericin–B procured by MoHFW has been allocated to States/UTs and Central Health Institutions free of cost.

Ministry of External Affairs (MEA) contacted various manufacturers abroad. Through its missions all over the world, MEA has identified new sources of Amphotericin B/ Liposomal Amphotericin B injections and alternative drugs for treatment of Mucormycosis.

For equitable distribution, allotments have been made to the States/ UTs in accordance with the proportion of their reported case load in respect of the entire country.

Supply arrangements have been monitored by the National Pharmaceuticals Pricing Authority (NPPA) so as to ensure expeditious availability of the drug.

NPPA has put in place a strongly responsive system to ensure timely supplies of allocated volumes and maintains continuous contact with States/UTs and suppliers to trouble shoot any issues in reaching the drugs to the Health Departments of States/ UTs.

Both first- and second-line drugs used for managing Mucormycosis cases i.e. Amphotericin B Deoxycholate and Posaconazole are currently amply available in Indian markets

During 2021(as on 21<sup>st</sup> November) total number of 1,64,103 dengue cases were reported as against 2,05,243 cases in 2019. Through the efforts of Government of India and States the Case Fatality Rate (deaths per 100 cases) has been sustained <1% since 2008. The case fatality rate has remained at extremely low level of 0.1% since 2019.

Some steps taken by MoHFW to tackle rise in Dengue cases in country are:

- In 2021, multidisciplinary Central Teams were deputed to 15 States and UTs of Gujarat, Haryana, Punjab, Kerala, Madhya Pradesh, Maharashtra, Odisha, Rajasthan, Tamil Nadu, Tripura, Uttar Pradesh, Telangana, Uttarakhand, Delhi and Jammu & Kashmir from 28th August to 19th November 2021.
- Government of India has shared National guidelines on Dengue case management during Covid-19 Pandemic, developed in consultation with experts, with all States/UTs.
- Government of India has also taken the following measures for prevention and control of dengue in the country:

- Provided Technical Guidelines for prevention and control, case management & effective community participation to the States for implementation. 15 advisories were issued from time to time to States/UTs for prevention and control of dengue in 2021.
- Free diagnostic facilities through 713 Sentinel Surveillance Hospitals and 17 Apex Referral laboratories identified across the country are fully functional. 7.26 Lakh IgM tests have been provided by Government of India. Additional fund has also been provided to states for procurement of NS1 kits for early diagnosis.
- The details of diagnostic facilities and IgM tests supplied to Rajasthan, Uttar Pradesh and Bihar is given below:

S.N.	State	Number of identified Sentinel Surveillance Hospitals	IgM tests supplied
1	Rajasthan	50	66,624
2	Uttar Pradesh	54	82,656
3	Bihar	9	4896

**Annexure I**State wise distribution of Mucormycosis Cases in India as on 29<sup>th</sup> Nov, 2021

<b>S.No</b>	<b>State/UT</b>	<b>Total Cases (Overall)</b>
1	Andaman & Nicobar	317
2	Andhra Pradesh	5107
3	Assam	12
4	Bihar	842
5	Chandigarh	739
6	Chhattisgarh	429
7	Delhi	2069
8	Goa	33
9	Gujarat	7257
10	Haryana	1792
11	Himachal Pradesh	38
12	Jammu and Kashmir	58
13	Jharkhand	132
14	Karnataka	4025
15	Kerala	148
16	Madhya Pradesh	2381
17	Maharashtra	10366
18	Manipur	8
19	Nagaland	1
20	Odisha	227
21	Puducherry	225
22	Punjab	691
23	Rajasthan	3711
24	Tamil Nadu	5007
25	Telangana	2638
26	Tripura	1
27	Uttar Pradesh	2603
28	Uttarakhand	590
29	West Bengal	328
	<b>TOTAL</b>	<b>51775</b>